Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Primary sclerosing cholangitis (PSC) is a rare and chronic liver disease for which there is no effective therapy. Interest has grown in developing treatments for this condition, with several agents proposed as potential therapies. However, there is a lack of clarity about how to measure clinical benefit in trials involving patients with this complex and rare disease. This article reviews regulatory information, the available literature on natural history, as well as potential candidate clinical and surrogate endpoints for PSC. (H epatology 2018; 00:000‐000).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Boonstra, K., Weersma, R. K., van Erpecum, K. J., Rauws, E. A., Spanier, B. W. M., Poen, A. C., van Nieuwkerk, K. M., Drenth, J. P., Witteman, B. J., Tuynman, H. A., et al. (2013) · Hepatology · doi:10.1002/hep.26565 · Cited by 725 · cited 5×
“This same figure has been observed in a large, population-based cohort of PSC patients.(5) This trial encompassed around 1,100 patient-years of follow-up, while they estimated to require 1,730 patient-years of follow-up to attain a power of 80%.”
BackgroundResultInfluentialSelf-citationHigh-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., et al. (2009) · Hepatology · doi:10.1002/hep.23082 · Cited by 720
Self-citationGregorio, G. (2001) · Hepatology · doi:10.1053/jhep.2001.22131 · Cited by 692 · cited 1×
“Interestingly, although treatment of the AIH component will result in normalization of all liver tests, autoantibody titers, and IgG level in >70% of cases, structural abnormalities of the bile ducts remain or progress over time, suggesting that autoantibodies and total IgG are diagnostic biomarkers of AIH; however, t…”
BackgroundEpidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review
Boonstra, K., Beuers, U., & Ponsioen, C. Y. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.025 · Cited by 632
Self-citationExtrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis
Millonig, G., Reimann, F. M., Friedrich, S., Fonouni, H., Mehrabi, A., Büchler, M. W., Seitz, H. K., & Mueller, S. (2008) · Hepatology · doi:10.1002/hep.22577 · Cited by 599
Ursodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598 · cited 1×
“There have been four randomized controlled clinical trials in PSC that used clinical events as primary outcome parameters with a follow-up ranging from 2 to 5 years.(33‒36) One trial studied colchicine and the other three investigated UDCA.”
MethodSelf-citationWeismüller, T. J., Trivedi, P. J., Bergquist, A., Imam, M., Lenzen, H., Ponsioen, C. Y., Holm, K., Gotthardt, D., Färkkilä, M. A., Marschall, H.-U., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.02.038 · Cited by 533 · cited 17×
“In three studies, no effect was observed on the occurrence of clinical outcomes such as TFS and cirrhosis-related symptoms.”
InfluentialSelf-citationNatural history and prognostic variables in primary sclerosing cholangitis
Farrant, J. M., Hayllar, K. M., Wilkinson, M. L., Karani, J., Portmann, B. C., Westaby, D., & Williams, R. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90673-9 · Cited by 468
Tischendorf, J. J. W., Hecker, H., Krüger, M., Manns, M. P., & Meier, P. N. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00872.x · Cited by 413
Olsson, R., Boberg, K. M., Schaffalitsky de Muckadell, O., Lindgren, S., Hultcrantz, R., Folvik, G., Bell, H., Gangsøy–Kristiansen, M., Matre, J., Rydning, A., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.08.017 · Cited by 394 · cited 1×
“There have been four randomized controlled clinical trials in PSC that used clinical events as primary outcome parameters with a follow-up ranging from 2 to 5 years.(33‒36) One trial studied colchicine and the other three investigated UDCA.”
MethodCharatcharoenwitthaya, P., Enders, F. B., Halling, K. C., & Lindor, K. D. (2008) · Hepatology · doi:10.1002/hep.22441 · Cited by 393 · cited 1×
“(6,27,28) In experienced hands, ultrasound may be an alternative, given that in a retrospective study from a tertiary referral center it was shown to have equal diagnostic performance with higher accuracy.(29) Chemoprevention trials could potentially be enriched to target patients that have no mass lesion on MRI/MRC a…”
BackgroundSelf-citationLevy, C., Lymp, J., Angulo, P., Gores, G. J., Larusso, N., & Lindor, K. D. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-2927-8 · Cited by 339 · cited 3×
“9) <130 U/mL would make the presence of CCA unlikely.(28) Accounting for CCA development during the course of a clinical trial is complex, given that this could be regarded either as a competing risk or as a clinical outcome and, depending on the mechanism of the drug, could be a primary, secondary, or safety endpoint.”
BackgroundInfluentialSelf-citationCorpechot, C., Gaouar, F., El Naggar, A., Kemgang, A., Wendum, D., Poupon, R., Carrat, F., & Chazouillères, O. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.030 · Cited by 300
Dave, M., Elmunzer, B. J., Dwamena, B. A., & Higgins, P. D. R. (2010) · Radiology · doi:10.1148/radiol.10091953 · Cited by 265
Deneau, M., Jensen, K. M., Holmen, J., Williams, M. S., Book, L. S., & Guthery, S. L. (2013) · Hepatology · doi:10.1002/hep.26454 · Cited by 233 · cited 2×
“Autoimmune sclerosing cholangitis or PSC/AIH overlap syndrome is quite common in children, with prevalences ranging from 25% to 75%.(50‒52) It is recommended that all children with a presumptive diagnosis of sclerosing cholangitis be screened for AIH with serum autoantibodies (antinuclear antibodies, anti-smooth muscl…”
BackgroundDeneau, M. R., El‐Matary, W., Valentino, P. L., Abdou, R., Alqoaer, K., Amin, M., Amir, A. Z., Auth, M., Bazerbachi, F., Broderick, A., et al. (2017) · Hepatology · doi:10.1002/hep.29204 · Cited by 230
Nakanuma, Y., Zen, Y., Harada, K., Sasaki, M., Nonomura, A., Uehara, T., Sano, K., Kondo, F., Fukusato, T., Tsuneyama, K., et al. (2010) · Pathology International · doi:10.1111/j.1440-1827.2009.02500.x · Cited by 224 · cited 1×
“Other relevant features include bile duct loss and accumulation of copper-associated protein in periportal hepatocytes indicative of cholestasis.(66) Histological features have been used in 12 published clinical trials of PSC.”
Rudolph, G., Gotthardt, D., Klöters-Plachky, P., Kulaksiz, H., Rost, D., & Stiehl, A. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.01.023 · Cited by 156
Ruiz, A., Lemoinne, S., Carrat, F., Corpechot, C., Chazouillères, O., & Arrivé, L. (2014) · Hepatology · doi:10.1002/hep.26620 · Cited by 144
Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis
Vesterhus, M., Hov, J. R., Holm, A., Schrumpf, E., Nygård, S., Godang, K., Andersen, I. M., Næss, S., Thorburn, D., Saffioti, F., et al. (2015) · Hepatology · doi:10.1002/hep.27825 · Cited by 138 · cited 1×
“Recently, the Enhanced Liver Fibrosis (ELF) score, a panel of three serum markers of fibrosis—hyaluronic acid, procollagen III aminoterminal peptide, and tissue inhibitor of metalloproteinase 1—was tested for its discriminative performance with regard to death or LT in a Norwegian study comprising 305 large-duct PSC p…”
MethodSelf-citationLiver alkaline phosphatase: a missing link between choleresis and biliary inflammation
Poupon, R. (2015) · Hepatology · doi:10.1002/hep.27715 · Cited by 120 · cited 1×
“In PBC, there is a rise in hepatocellular bile acids secondary to reduced canalicular secretion and rise in serum ALP secondary to its release into the bloodstream rather than secretion of ALP into bile.(46) Thus, ALP is a biomarker that reflects bile acid retention in PBC patients and may reflect a similar process in…”
Aabakken, L., Karlsen, T. H., Albert, J., Arvanitakis, M., Chazouilleres, O., Dumonceau, J.-M., Färkkilä, M., Fickert, P., Hirschfield, G. M., Laghi, A., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.013 · Cited by 107
Self-citationBeyond scoring: a modern interpretation of disease progression in chronic liver disease
Rosselli, M., MacNaughtan, J., Jalan, R., & Pinzani, M. (2013) · Gut · doi:10.1136/gutjnl-2012-302826 · Cited by 96 · cited 1×
“1185 hepatitis.(76) Baseline hepatic collagen content was also shown to correlate with Ishak fibrosis stage and has a potential to evaluate progression of fibrosis; however, the data are still preliminary.”
Backgroundde Vries, E. M. G., Färkkilä, M., Milkiewicz, P., Hov, J. R., Eksteen, B., Thorburn, D., Chazouillères, O., Pares, A., Nygård, S., Gilja, O. H., et al. (2017) · Liver International · doi:10.1111/liv.13402 · Cited by 83 · cited 1×
“A validation study in external cohorts from seven countries confirmed the previous data.(49) As with other serum biomarkers, ELF can be elevated secondary to acute inflammation or obstruction, and these need to be accounted for assessing responses.”
MethodSelf-citationKakuda, Y., Harada, K., Sawada-Kitamura, S., Ikeda, H., Sato, Y., Sasaki, M., Okafuji, H., Mizukoshi, E., Terasaki, S., Ohta, H., et al. (2013) · Human Pathology · doi:10.1016/j.humpath.2012.09.017 · Cited by 81 · cited 1×
“,(71) which incorporates features indicative of disease progression in chronic biliary diseases such as fibrosis, ductopenia, and orcein-positive granules, were assessed in 64 PSC patients as to its ability to predict clinical outcome.”
BackgroundFevery, J., Van Steenbergen, W., Van Pelt, J., Laleman, W., Hoffman, I., Geboes, K., Vermeire, S., & Nevens, F. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13516 · Cited by 61
Cited by
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
Bowlus, C. L., Arrivé, L., Bergquist, A., Deneau, M., Forman, L., Ilyas, S. I., Lunsford, K. E., Martinez, M., Sapisochin, G., Shroff, R., et al. (2023) · Hepatology · doi:10.1002/hep.32771 · Cited by 428
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Trauner, M., Gulamhusein, A., Hameed, B., Caldwell, S., Shiffman, M. L., Landis, C., Eksteen, B., Agarwal, K., Muir, A., Rushbrook, S., et al. (2019) · Hepatology · doi:10.1002/hep.30509 · Cited by 261
Hirschfield, G. M., Chazouillères, O., Drenth, J. P., Thorburn, D., Harrison, S. A., Landis, C. S., Mayo, M. J., Muir, A. J., Trotter, J. F., Leeming, D. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.035 · Cited by 187
Pape, S., Snijders, R. J. A. L. M., Gevers, T. J. G., Chazouilleres, O., Dalekos, G. N., Hirschfield, G. M., Lenzi, M., Trauner, M., Manns, M. P., Vierling, J. M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.041 · Cited by 177
Metadata
- Authors
- Ponsioen, C. Y., Lindor, K. D., Mehta, R., & Dimick‐Santos, L.
- Venue
- Hepatology
- Published
- 2018-08-31
- Volume
- 68
- Issue
- 3
- Pages
- 1174-1188
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2790255143
- Cited by
- 75
- References
- 27
- FWCI
- 3.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.